Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | JUN | P05412 | 2/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.40 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.40 |
| ▸ | RELA | Q04206 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | CASP6 | P55212 | 1/20 | 0.35 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23695123 | 0.79 | ALDH1A1 (0.42) | ALDH1A1SMN1; SMN2L3MBTL1JUNNFKB1 | |
| SCHEMBL5409166 | 0.79 | ALDH1A1 (0.42) | ALDH1A1SMN1; SMN2L3MBTL1KMT2AMAPT | |
| SCHEMBL14390103 | 0.79 | ALDH1A1 (0.42) | ALDH1A1SMN1; SMN2L3MBTL1KMT2AMAPT | |
| SCHEMBL15282441 | 0.79 | ALDH1A1 (0.42) | ALDH1A1SMN1; SMN2L3MBTL1JUNNFKB1 | |
| SCHEMBL24922312 | 0.79 | ALDH1A1 (0.39) | ALDH1A1SMN1; SMN2L3MBTL1JUNNFKB1 | |
| SCHEMBL29038093 | 0.78 | JUN (0.39) | ALDH1A1SMN1; SMN2JUNNFKB1NFKB2 | |
| SCHEMBL30519922 | 0.78 | JUN (0.39) | ALDH1A1SMN1; SMN2JUNNFKB1NFKB2 | |
| SCHEMBL1427749 | 0.78 | ALDH1A1 (0.41) | ALDH1A1SMN1; SMN2L3MBTL1JUNNFKB1 | |
| SCHEMBL10523216 | 0.77 | JUN (0.41) | ALDH1A1SMN1; SMN2JUNNFKB1NFKB2 | |
| SCHEMBL16741140 | 0.77 | JUN (0.41) | ALDH1A1SMN1; SMN2JUNNFKB1NFKB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240400555-A1 | Compounds, Compositions and Methods for Attenuation of Mammalian Translation of C-MYC or N-MYC Proteins of the MYC Proto-Oncogene Family of BHLH Transcription Factors | INITIAL THERAPEUTICS, INC. (US) | 2024-12-05 | — | — | US | disclosed |
| WO-2024226875-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR ATTENUATION OF MAMMALIAN TRANSLATION OF C-MYC OR N-MYC PROTEINS OF THE MYC PROTO-ONCOGENE FAMILY OF BHLH TRANSCRIPTION FACTORS | INITIAL THERAPEUTICS, INC. (US) | 2024-10-31 | — | — | WO | disclosed |
| CN-116106434-A | Method for efficiently detecting related substances in 4-chloro-6-ethyl-5-fluoropyrimidine | 南京易亨制药有限公司 | 2023-05-12 | — | — | CN | disclosed |
| EP-2912041-B1 | TETRAHYDROPYRROLOTHIAZINE DERIVATIVES AS BACE INHIBITORS | LILLY CO ELI (US) | 2016-12-14 | — | — | EP | disclosed |
| EP-2912041-B1 | TETRAHYDROPYRROLOTHIAZINE DERIVATIVES AS BACE INHIBITORS | LILLY CO ELI (US) | 2016-12-14 | — | — | EP | disclosed |
| EP-2836495-B1 | TETRAHYDROPYRROLOTHIAZINE COMPOUNDS | LILLY CO ELI (US) | 2016-05-18 | — | — | EP | disclosed |
| EP-2836495-B1 | TETRAHYDROPYRROLOTHIAZINE COMPOUNDS | LILLY CO ELI (US) | 2016-05-18 | — | — | EP | disclosed |
| US-9328124-B2 | BACE inhibitors | ELI LILLY AND COMPANY (US) | 2016-05-03 | — | — | US | disclosed |
| US-9328124-B2 | BACE inhibitors | ELI LILLY AND COMPANY (US) | 2016-05-03 | — | — | US | disclosed |
| US-9328124-B2 | BACE inhibitors | ELI LILLY AND COMPANY (US) | 2016-05-03 | — | — | US | disclosed |
| US-20130261111-A1 | TETRAHYDROPYRROLOTHIAZINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2013-10-03 | — | — | US | disclosed |
| US-20130261111-A1 | TETRAHYDROPYRROLOTHIAZINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2013-10-03 | — | — | US | disclosed |
| WO-2012129338-A1 | AZOLE COMPOUNDS AS PIM INHIBITORS | AMGEN INC. (US) | 2012-09-27 | — | — | WO | disclosed |
| WO-2012129338-A1 | AZOLE COMPOUNDS AS PIM INHIBITORS | AMGEN INC. (US) | 2012-09-27 | — | — | WO | disclosed |
| US-20090325964-A1 | Piperazine Metabotropic Glutamate Receptor 5 (MGLUR5) Negative Allosteric Modulators For Anxiety/Depression | WYETH (US) | 2009-12-31 | — | — | US | disclosed |
| US-5773443-A | Triazole antifungal agents | PFIZER INC. (US) | 1998-06-30 | — | — | US | disclosed |
| US-5567817-A | Triazole antifungal agents | PFIZER INC. (US) | 1996-10-22 | — | — | US | disclosed |
| US-5278175-A | Halopyridyl fungicides | PFIZER INC. (US) | 1994-01-11 | — | — | US | disclosed |
| EP-0440372-B1 | TRIAZOLE ANTIFUNGAL AGENTS | Pfizer Limited (GB) | 1993-06-02 | — | — | EP | disclosed |
| EP-0440372-A1 | Triazole antifungal agents | Pfizer Limited (GB) | 1991-08-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325964-A1 | Piperazine Metabotropic Glutamate Receptor 5 (MGLUR5) Negative Allosteric Modulators For Anxiety/Depression | GRM5, GRIK5, GRM1 | ALDH1A1 3104/4885SMN1; SMN2 3956/4885L3MBTL1 4431/4885 |
| US-20130261111-A1 | TETRAHYDROPYRROLOTHIAZINE COMPOUNDS | HRH4, HRH3, HRH1 | ALDH1A1 980/4885SMN1; SMN2 4553/4885L3MBTL1 3773/4885 |
| US-20240400555-A1 | Compounds, Compositions and Methods for Attenuation of Mammalian Translation of C-MYC or N-MYC Proteins of the MYC Proto-Oncogene Family of BHLH Transcription Factors | MYCBP, MYC, MYCBP2 | ALDH1A1 3684/4885SMN1; SMN2 3533/4885L3MBTL1 1065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.